Darolutamide and Equetro

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent or moderate inducers of CYP450 3A4 that also induce P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter. Reduced efficacy of darolutamide may occur. When darolutamide was coadministered with rifampin, a dual P-gp and potent CYP450 3A4 inducer, mean darolutamide peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 52% and 72%, respectively, compared to administration of darolutamide alone. The decrease in darolutamide exposure by moderate CYP450 3A4 inducers is expected to be in the range of 36% to 58% according to the prescribing information. MANAGEMENT: Concomitant use of darolutamide with dual P-gp and potent or moderate CYP450 3A4 inducers should generally be avoided. References "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.

GENERALLY AVOID: Coadministration with potent or moderate inducers of CYP450 3A4 that also induce P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter. Reduced efficacy of darolutamide may occur. When darolutamide was coadministered with rifampin, a dual P-gp and potent CYP450 3A4 inducer, mean darolutamide peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 52% and 72%, respectively, compared to administration of darolutamide alone. The decrease in darolutamide exposure by moderate CYP450 3A4 inducers is expected to be in the range of 36% to 58% according to the prescribing information.

MANAGEMENT: Concomitant use of darolutamide with dual P-gp and potent or moderate CYP450 3A4 inducers should generally be avoided.

Darolutamide

Generic Name: darolutamide

Brand name: Nubeqa

Synonyms: n.a.

What is Darolutamide?

Equetro

Generic Name: carbamazepine

Brand name: Carbatrol, Epitol, Equetro, Tegretol, Tegretol XR, Tegretol, Tegretol XR

Synonyms: n.a.

What is Equetro?